In search of a standard when analyzing medication adherence in patients with heart failure using claims data: a

Katrin Krueger1, Nina Griese-Mammen1, Ingrid Schubert2

  • 1Department of Medicine, ABDA - Federal Union of German Associations of Pharmacists, Unter den Linden 19-23, D-10117, Berlin, Germany.

Heart Failure Reviews
|October 11, 2017
PubMed

Insights

Medication non-adherence in heart failure patients is a significant issue. This review found varied methods for measuring adherence using claims data, highlighting a need for standardized reporting to improve patient outcomes.

Area of Science:

  • Pharmacoeconomics
  • Health Services Research
  • Cardiology

Background:

  • Medication non-adherence is a critical factor impacting patient outcomes in heart failure.
  • Claims data offer a valuable resource for assessing adherence in large populations.
  • Standardized methods for operationalizing adherence measures are lacking.

Purpose of the Study:

  • To systematically review the operationalization of medication adherence measures in heart failure patients using claims data.
  • To identify common methodologies and variations in adherence assessment.
  • To highlight areas for improvement in reporting adherence measurement.

Main Methods:

  • Systematic literature search of MEDLINE, EMBASE, and Cochrane databases.
  • Inclusion of 28 studies assessing medication adherence in heart failure.
  • Quality assessment using the Quality in Prognosis Studies tool.

Main Results:

  • Medication possession ratio (11 studies) and proportion of days covered (15 studies) were common adherence measures.
  • Wide variation existed in assumptions for dosage, switching within classes, stockpiling, and censoring events (hospital stays, death).
  • Reporting quality of methodologies varied significantly, with no gold standard identified.

Conclusions:

  • Current methods for quantifying medication adherence in heart failure using claims data lack standardization.
  • Comprehensive reporting of methodological parameters is essential for accurate assessment.
  • Standardized approaches are needed to improve the reliability and comparability of adherence research.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
392
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.6K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
430